Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife)

PHASE4CompletedINTERVENTIONAL

Enrollment

196

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions

Renal TransplantationGastrointestinal Problems

Interventions

DRUG

Enteric-Coated Mycophenolate Sodium (EC-MPS)

Patient on MMF treatment completes questionnaire and switch to equimolar doses of Myfortic. Maximum daily dose 1440 mg

Trial Locations (2)

Bonn

Novartis, Basel